On October 16, 2024, William Hoffman, Director at Inari Medical Inc (NARI, Financial), executed a sale of 40,000 shares of the company. The transaction was filed on the same day through an SEC Filing. Following this transaction, the insider now owns 601,233 shares of Inari Medical Inc.
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. The company's innovative devices are specifically designed to remove blood clots and restore blood flow, contributing to the rapidly growing field of vascular treatment.
Over the past year, William Hoffman has sold a total of 490,000 shares and has not made any purchases of the stock. This recent sale is part of a broader trend observed within the company, where there have been 32 insider sells and only 2 insider buys over the past year.
On the date of the recent transaction, shares of Inari Medical Inc were priced at $45.02. The company has a market cap of approximately $2.577 billion. According to the GF Value, the intrinsic value of the stock is estimated at $90.15, indicating a price-to-GF-Value ratio of 0.5. This suggests that the stock might be a Possible Value Trap, and investors should think twice before making an investment decision.
The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This insider selling activity could be of interest to current and potential investors, as it provides insight into the insider's perspective on the stock's valuation and future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
